Gasdermin E: A Prospective Target for Therapy of Diseases

38Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Gasdermin E (GSDME) is a member of the gasdermin protein family, which mediates programmed cell death including apoptosis and pyroptosis. Recently, it was suggested that GSDME is activated by chemotherapeutic drugs to stimulate pyroptosis of cancer cells and trigger anti-tumor immunity, which is identified as a tumor suppressor. However, GSDME-mediated pyroptosis contributes to normal tissue damage, leading to pathological inflammations. Inhibiting GSDME-mediated pyroptosis might be a potential target in ameliorating inflammatory diseases. Therefore, targeting GSDME is a promising option for the treatment of diseases in the future. In this review, we introduce the roles of GSDME-driven programmed cell death in different diseases and the potential targeted therapies of GSDME, so as to provide a foundation for future research.

Cite

CITATION STYLE

APA

Liao, X. X., Dai, Y. Z., Zhao, Y. Z., & Nie, K. (2022, April 6). Gasdermin E: A Prospective Target for Therapy of Diseases. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.855828

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free